---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-028595"
form_type: "8-K"
ticker: "FENC"
cik: "0001211583"
company_name: "FENNEC PHARMACEUTICALS INC."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:25:47.072969+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Fennec settles PEDMARK patent litigation; Cipla barred from generic until 2033

## Summary
- Lawsuit dismissed; each party bears its own costs.
- Cipla agrees not to launch generic sodium thiosulfate in U.S. until September 1, 2033, subject to earlier entry under specified circumstances.
- Settlement covers Cipla's ANDA for generic PEDMARK, resolving litigation in D.N.J.
- Press release issued March 16, 2026 announcing the agreement.

## SEC filing metadata
- accession: 0001104659-26-028595
- form_type: 8-K
- ticker: FENC
- cik: 0001211583
- company_name: FENNEC PHARMACEUTICALS INC.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1211583/000110465926028595/0001104659-26-028595-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1211583/000110465926028595/fencf-20260316x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-028595
- JSON: https://secwatch.observer/filing/0001104659-26-028595.json
- Plain text: https://secwatch.observer/filing/0001104659-26-028595.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.